Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $205.2 million.

  • Amphastar Pharmaceuticals' Total Current Liabilities rose 2906.55% to $205.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $205.2 million, marking a year-over-year increase of 2906.55%. This contributed to the annual value of $173.8 million for FY2024, which is 2291.32% down from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Total Current Liabilities stood at $205.2 million, which was up 2906.55% from $176.4 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Total Current Liabilities' 5-year high stood at $258.0 million during Q3 2023, with a 5-year trough of $94.9 million in Q4 2022.
  • In the last 5 years, Amphastar Pharmaceuticals' Total Current Liabilities had a median value of $137.0 million in 2024 and averaged $158.7 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Total Current Liabilities soared by 15243.47% in 2023 and then tumbled by 4549.18% in 2024.
  • Over the past 5 years, Amphastar Pharmaceuticals' Total Current Liabilities (Quarter) stood at $103.8 million in 2021, then fell by 8.62% to $94.9 million in 2022, then skyrocketed by 137.62% to $225.4 million in 2023, then decreased by 22.91% to $173.8 million in 2024, then increased by 18.11% to $205.2 million in 2025.
  • Its Total Current Liabilities stands at $205.2 million for Q3 2025, versus $176.4 million for Q2 2025 and $199.1 million for Q1 2025.